Cannabinoid receptor 1 (CNR1) gene variant moderates neural index of cognitive disruption during nicotine withdrawal
- PMID: 27453054
- PMCID: PMC6027743
- DOI: 10.1111/gbb.12311
Cannabinoid receptor 1 (CNR1) gene variant moderates neural index of cognitive disruption during nicotine withdrawal
Abstract
Nicotine withdrawal-related disruption of cognitive control may contribute to the reinforcement of tobacco use. Identification of gene variants that predict this withdrawal phenotype may lead to tailored pharmacotherapy for smoking cessation. Variation on the cannabinoid receptor 1 gene (CNR1) has been related to nicotine dependence, and CNR1 antagonists may increase attention and memory functioning. We targeted CNR1 variants as moderators of a validated neural marker of nicotine withdrawal-related cognitive disruption. CNR1 polymorphisms comprising the 'TAG' haplotype (rs806379, rs1535255 and rs2023239) were tested independently, as no participants in this sample possessed this haplotype. Nicotine withdrawal-related cognitive disruption was indexed as increased resting electroencephalogram (EEG) alpha-1 power density across 17 electrodes. Seventy-three Caucasian Non-Hispanic smokers (≥15 cigarettes per day) visited the laboratory on two occasions following overnight smoking/nicotine deprivation. Either two nicotine or two placebo cigarettes were smoked prior to collecting EEG data at each session. Analyses showed that rs806379 moderated the effects of nicotine deprivation increasing slow wave EEG (P = 0.004). Smokers homozygous for the major allele exhibited greater nicotine withdrawal-related cognitive disruption. The current findings suggest potential efficacy of cannabinoid receptor antagonism as a pharmacotherapy approach for smoking cessation among individuals who exhibit greater nicotine withdrawal-related cognitive disruption.
Keywords: Alpha-1; CNR1; EEG; ERP; cannabinoid; cognitive control; genetics; nicotine withdrawal; smoking.
© 2016 John Wiley & Sons Ltd and International Behavioural and Neural Genetics Society.
Conflict of interest statement
Conflict of Interest
None of the authors have potential conflicts of interest (financial or other) regarding information reported herein. David Drobes has served as an expert witness in litigation against tobacco companies.
Figures

Similar articles
-
Cortical activity differs during nicotine deprivation versus satiation in heavy smokers.Psychopharmacology (Berl). 2015 Jun;232(11):1879-85. doi: 10.1007/s00213-014-3821-x. Epub 2014 Dec 10. Psychopharmacology (Berl). 2015. PMID: 25491928 Free PMC article.
-
CHRNA5 variants moderate the effect of nicotine deprivation on a neural index of cognitive control.Genes Brain Behav. 2014 Sep;13(7):626-32. doi: 10.1111/gbb.12151. Epub 2014 Jul 23. Genes Brain Behav. 2014. PMID: 24934182 Free PMC article.
-
Cannabinoid receptor 1 gene association with nicotine dependence.Arch Gen Psychiatry. 2008 Jul;65(7):816-24. doi: 10.1001/archpsyc.65.7.816. Arch Gen Psychiatry. 2008. PMID: 18606954 Free PMC article.
-
Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal.Expert Opin Drug Discov. 2014 Jun;9(6):579-94. doi: 10.1517/17460441.2014.908180. Epub 2014 Apr 7. Expert Opin Drug Discov. 2014. PMID: 24707983 Free PMC article. Review.
-
Smoking and Cognition.Curr Drug Abuse Rev. 2016;9(2):76-79. doi: 10.2174/1874473709666160803101633. Curr Drug Abuse Rev. 2016. PMID: 27492358 Review.
Cited by
-
Quantitative biochemical screening for marijuana use and concordance with tobacco use in urban adolescents.Drug Alcohol Depend. 2019 Dec 1;205:107583. doi: 10.1016/j.drugalcdep.2019.107583. Epub 2019 Sep 25. Drug Alcohol Depend. 2019. PMID: 31600618 Free PMC article.
-
Influence of Cannabinoid Receptor 1 Genetic Variants on the Subjective Effects of Smoked Cannabis.Int J Mol Sci. 2021 Jul 9;22(14):7388. doi: 10.3390/ijms22147388. Int J Mol Sci. 2021. PMID: 34299009 Free PMC article.
-
Biomarkers of the Endocannabinoid System in Substance Use Disorders.Biomolecules. 2022 Mar 3;12(3):396. doi: 10.3390/biom12030396. Biomolecules. 2022. PMID: 35327588 Free PMC article. Review.
-
Cannabinoid receptor CNR1 expression and DNA methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia.Transl Psychiatry. 2020 May 19;10(1):158. doi: 10.1038/s41398-020-0832-8. Transl Psychiatry. 2020. PMID: 32433545 Free PMC article.
-
Identification of a sex-stratified genetic algorithm for opioid addiction risk.Pharmacogenomics J. 2021 Jun;21(3):326-335. doi: 10.1038/s41397-021-00212-0. Epub 2021 Feb 15. Pharmacogenomics J. 2021. PMID: 33589790
References
-
- Clarke AR, Barry RJ, Bond D, McCarthy R, Selikowitz M (2002) Effects of stimulant medications on the EEG of children with attention-deficit/hyperactivity disorder. Psychopharmacology 164, 277–284. - PubMed
-
- Cohen C, Perrault G, Voltz C, Steinberg R & Soubrie P (2002) SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13, 451–463. - PubMed
-
- Degroot A, Kofalvi A, Wade MR, Davis RJ, Rodrigues RJ, Rebola N, Cunha RA & Nomikos GG (2006) CB1 receptor antagonism increases hippocampal acetylcholine release: site and mechanism of action. Mol Pharmacol 70, 1236–1245. - PubMed
-
- Dien J (2010) Evaluating two‐step PCA of ERP data with geomin, infomax, oblimin, promax, and varimax rotations. Psychophysiology 47, 170–183. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources